Medivir AB - Product Pipeline Review - 2014

Date: November 30, 2014
Pages: 41
Price:
US$ 1,500.00 US$ 1,350.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M0CD4C95A4CEN
Leaflet:

Download PDF Leaflet

Medivir AB - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Medivir AB - Product Pipeline Review - 2014’, provides an overview of the Medivir AB’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Medivir AB’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Medivir AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Medivir AB’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Medivir AB’s pipeline products
Reasons to buy
  • Evaluate Medivir AB’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Medivir AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Medivir AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Medivir AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Medivir AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Medivir AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Medivir AB Snapshot
Medivir AB Overview
Key Information
Key Facts
Medivir AB - Research and Development Overview
Key Therapeutic Areas
Medivir AB - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Medivir AB - Pipeline Products Glance
Medivir AB - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Medivir AB - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Medivir AB - Drug Profiles
MIV-711
Product Description
Mechanism of Action
R&D Progress
MIV-150
Product Description
Mechanism of Action
R&D Progress
MIV-247
Product Description
Mechanism of Action
R&D Progress
MIV-710
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit HCV Polymerase for Hepatitis C
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NS5B Nucleotide Polymerase for Hepatitis C
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Renin for Hypertension
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit HIV Protease for HIV Infection
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NS3 Protease for Dengue
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Fusion Protein for RSV Infections
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Proteases for Infectious Diseases
Product Description
Mechanism of Action
R&D Progress
Medivir AB - Pipeline Analysis
Medivir AB - Pipeline Products by Target
Medivir AB - Pipeline Products by Route of Administration
Medivir AB - Pipeline Products by Molecule Type
Medivir AB - Pipeline Products by Mechanism of Action
Medivir AB - Recent Pipeline Updates
Medivir AB - Dormant Projects
Medivir AB - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
lagociclovir
MIV-150
MIV-701
Small Molecule to Inhibit BACE for Alzheimer Disease
Small Molecule to Inhibit NS5A for Hepatitis C
TMC-649128
Medivir AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABES

Medivir AB, Key Information
Medivir AB, Key Facts
Medivir AB - Pipeline by Indication, 2014
Medivir AB - Pipeline by Stage of Development, 2014
Medivir AB - Monotherapy Products in Pipeline, 2014
Medivir AB - Partnered Products in Pipeline, 2014
Medivir AB - Partnered Products/ Combination Treatment Modalities, 2014
Medivir AB - Out-Licensed Products in Pipeline, 2014
Medivir AB - Out-Licensed Products/ Combination Treatment Modalities, 2014
Medivir AB - Phase I, 2014
Medivir AB - Preclinical, 2014
Medivir AB - Discovery, 2014
Medivir AB - Pipeline by Target, 2014
Medivir AB - Pipeline by Route of Administration, 2014
Medivir AB - Pipeline by Molecule Type, 2014
Medivir AB - Pipeline Products by Mechanism of Action, 2014
Medivir AB - Recent Pipeline Updates, 2014
Medivir AB - Dormant Developmental Projects,2014
Medivir AB - Discontinued Pipeline Products, 2014
Medivir AB, Other Locations
Medivir AB, Subsidiaries

LIST OF FIGURES

Medivir AB - Pipeline by Top 10 Indication, 2014
Medivir AB - Pipeline by Stage of Development, 2014
Medivir AB - Monotherapy Products in Pipeline, 2014
Medivir AB - Out-Licensed Products in Pipeline, 2014
Medivir AB - Pipeline by Top 10 Target, 2014
Medivir AB - Pipeline by Top 10 Route of Administration, 2014
Medivir AB - Pipeline by Top 10 Molecule Type, 2014
Medivir AB - Pipeline Products by Top 10 Mechanism of Action, 2014

Ask Your Question

Medivir AB - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: